# The Stiff Side of Cancer: How Matrix Mechanics Rewrites Non-Coding RNA Expression Programs

**Authors:** Alma D. Campos-Parra, Jonathan Puente-Rivera, César López-Camarillo, Stephanie I. Nuñez-Olvera, Nereyda Hernández Nava, Gabriela Alvarado Macias, Macrina Beatriz Silva-Cázares

PMC · DOI: 10.3390/ncrna12010007 · Non-Coding RNA · 2026-02-18

## TL;DR

This paper explores how the stiffness of the tumor environment influences non-coding RNA expression, shaping cancer progression and treatment resistance.

## Contribution

The paper introduces a framework linking ECM mechanics to ncRNA regulation, identifying mechanosensitive RNA programs in tumors and stroma.

## Key findings

- Matrix stiffness modulates miRNA and lncRNA expression in tumor and stromal cells.
- Mechanosensitive ncRNAs influence metastasis through extracellular vesicle cargo.
- ceRNA networks converge on mechanotransduction hubs like YAP1 and LOX.

## Abstract

Extracellular matrix (ECM) stiffening is a defining biophysical feature of solid tumors that reshape gene regulation through mechanotransduction. Increased collagen crosslinking and stromal remodeling enhance integrin engagement, focal-adhesion signaling and force transmission to the nucleus, where key hubs such as lysyl oxidase (LOX), focal adhesion kinase (FAK) and the Hippo co-activators YAP1 and TAZ (WWTR1) promote proliferation, invasion, stemness and therapy resistance. Here, we synthesize evidence that quantitative changes in matrix stiffness remodel the miRNome and lncRNome in both tumor and stromal compartments, including extracellular vesicle cargo that reprograms metastatic niches. To address heterogeneity in experimental support, we classify mechanosensitive ncRNAs into studies directly validated by stiffness manipulation (e.g., tunable hydrogels/AFM) versus indirect associations based on mechanosensitive signaling, and we summarize physiological versus pathophysiological stiffness ranges across tissues discussed. We further review competing endogenous RNA (ceRNA) networks converging on mechanotransduction nodes and ECM remodeling enzymes, and discuss translational opportunities and challenges, including targeting mechanosensitive ncRNAs, combining ncRNA modulation with anti-stiffening strategies, delivery barriers in dense tumors, and the potential of circulating/exosomal ncRNAs as biomarkers. Overall, integrating ECM mechanics with ncRNA regulatory circuits provides a framework to identify feed-forward loops sustaining aggressive phenotypes in rigid microenvironments and highlights priorities for validation in physiologically relevant models.

## Linked entities

- **Genes:** LOX (lysyl oxidase) [NCBI Gene 4015], PTK2 (protein tyrosine kinase 2) [NCBI Gene 5747], YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413], WWTR1 (WW domain containing transcription regulator 1) [NCBI Gene 25937], TAFAZZIN (tafazzin, phospholipid-lysophospholipid transacylase) [NCBI Gene 6901]

## Full-text entities

- **Genes:** PVT1 (Pvt1 oncogene) [NCBI Gene 5820] {aka LINC00079, MIR1204HG, NCRNA00079, TP53LC09, onco-lncRNA-100}, MIR4435-2HG (MIR4435-2 host gene) [NCBI Gene 541471] {aka AGD2, LINC00978, MIR4435-1HG, MORRBID, lncRNA-AWPPH}, TRPC4AP (transient receptor potential cation channel subfamily C member 4 associated protein) [NCBI Gene 26133] {aka C20orf188, PPP1R158, TRRP4AP, TRUSS}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, PIEZO1 (piezo type mechanosensitive ion channel component 1 (Er blood group)) [NCBI Gene 9780] {aka DHS, ER, FAM38A, LMPH3, LMPHM6, Mib}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, KDR (kinase insert domain receptor) [NCBI Gene 3791] {aka CD309, FLK1, VEGFR, VEGFR2}, LATS1 (large tumor suppressor kinase 1) [NCBI Gene 9113] {aka WARTS, wts}, SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714] {aka ASV, SRC1, THC6, c-SRC, p60-Src}, MIR214 (microRNA 214) [NCBI Gene 406996] {aka MIRN214, miRNA214, mir-214}, PTK2 (protein tyrosine kinase 2) [NCBI Gene 5747] {aka FADK, FADK 1, FAK, FAK1, FRNK, PPP1R71}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, HAS2 (hyaluronan synthase 2) [NCBI Gene 3037], PXN (paxillin) [NCBI Gene 5829], CD24 (CD24 molecule) [NCBI Gene 100133941] {aka CD24A}, COL11A1 (collagen type XI alpha 1 chain) [NCBI Gene 1301] {aka CO11A1, COLL6, DFNA37, STL2}, CXCL1 (C-X-C motif chemokine ligand 1) [NCBI Gene 2919] {aka FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3}, PFKP (phosphofructokinase, platelet) [NCBI Gene 5214] {aka ATP-PFK, PFK-C, PFK-P, PFKF}, TAFAZZIN (tafazzin, phospholipid-lysophospholipid transacylase) [NCBI Gene 6901] {aka BTHS, CMD3A, EFE, EFE2, G4.5, LVNCX}, FAS (Fas cell surface death receptor) [NCBI Gene 355] {aka ALPS1A, APO-1, APT1, CD95, FAS1, FASTM}, KLF2 (KLF transcription factor 2) [NCBI Gene 10365] {aka LKLF}, TNS2 (tensin 2) [NCBI Gene 23371] {aka C1-TEN, C1TEN, TENC1}, LINC01270 (long intergenic non-protein coding RNA 1270) [NCBI Gene 284751], TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, KLF4 (KLF transcription factor 4) [NCBI Gene 9314] {aka EZF, GKLF}, SNHG9 (small nucleolar RNA host gene 9) [NCBI Gene 735301] {aka NCRNA00062}, MIR211 (microRNA 211) [NCBI Gene 406993] {aka MIRN211, mir-211}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, E2F1 (E2F transcription factor 1) [NCBI Gene 1869] {aka E2F-1, RBAP1, RBBP3, RBP3}, CAMK2G (calcium/calmodulin dependent protein kinase II gamma) [NCBI Gene 818] {aka CAMK, CAMK-II, CAMKG, MRD59}, STEAP4 (STEAP4 metalloreductase) [NCBI Gene 79689] {aka STAMP2, SchLAH, TIARP, TNFAIP9}, VIM (vimentin) [NCBI Gene 7431], MIR1297 (microRNA 1297) [NCBI Gene 100302187] {aka MIRN1297, hsa-mir-1297, mir-1297}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, ELN (elastin) [NCBI Gene 2006] {aka ADCL1, SVAS, WBS, WS}, NEAT1 (nuclear paraspeckle assembly transcript 1) [NCBI Gene 283131] {aka LINC00084, NCRNA00084, TP53LC15, TncRNA, VINC}, MIR29C (microRNA 29c) [NCBI Gene 407026] {aka MIRN29C, miRNA29C, mir-29c}, EZR (ezrin) [NCBI Gene 7430] {aka CVIL, CVL, HEL-S-105, VIL2}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}, CFL1 (cofilin 1) [NCBI Gene 1072] {aka CFL, HEL-S-15, cofilin}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513] {aka CSE, DYT17, DYT18, DYT9, EIG12, GLUT}, ACTA1 (actin alpha 1, skeletal muscle) [NCBI Gene 58] {aka ACTA, ASMA, CFTD, CFTD1, CFTDM, CMYO2A}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, SPTB (spectrin beta, erythrocytic) [NCBI Gene 6710] {aka EL3, HS2, HSPTB1, SPH2}, MIR2115 (microRNA 2115) [NCBI Gene 100313840], PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, COL4A1 (collagen type IV alpha 1 chain) [NCBI Gene 1282] {aka BSVD, BSVD1, COL4A1s, PADMAL, RATOR}, ACTA2 (actin alpha 2, smooth muscle) [NCBI Gene 59] {aka ACTSA, SMDYS}, YBX1 (Y-box binding protein 1) [NCBI Gene 4904] {aka BP-8, CBF-A, CSDA2, CSDB, DBPB, EFI-A}, MIR1246 (microRNA 1246) [NCBI Gene 100302142] {aka MIRN1246, hsa-mir-1246}, PHLDA1 (pleckstrin homology like domain family A member 1) [NCBI Gene 22822] {aka DT1P1B11, PHRIP, TDAG51}, AMOT (angiomotin) [NCBI Gene 154796], WWTR1 (WW domain containing transcription regulator 1) [NCBI Gene 25937] {aka TAZ}, MIR30A (microRNA 30a) [NCBI Gene 407029] {aka MIRN30A, mir-30a}, MIR455 (microRNA 455) [NCBI Gene 619556] {aka MIRN455, hsa-mir-455, mir-455}, VCL (vinculin) [NCBI Gene 7414] {aka CMD1W, CMH15, HEL114, MV, MVCL, VINC}
- **Diseases:** osteosarcoma (MESH:D012516), inflammation (MESH:D007249), injury to (MESH:D014947), metastasis (MESH:D009362), prostate cancer (MESH:D011471), glioma (MESH:D005910), cirrhosis (MESH:D005355), CRC (MESH:D015179), lung carcinoma (MESH:D008175), Tumors (MESH:D009369), metastatic disease (MESH:D000092182), lymph node involvement (MESH:D000072717), breast cancer (MESH:D001943), TNBC (MESH:D064726), gastric cancer (MESH:D013274), ovarian cancer (MESH:D010051), epithelial ovarian cancer (MESH:D000077216), HCC (MESH:D006528), bladder cancer (MESH:D001749), head and neck squamous cell carcinoma (MESH:D000077195), solid (MESH:D018250)
- **Chemicals:** Ca2+ (-), PEGDA (MESH:C437167), cisplatin (MESH:D002945), blebbistatin (MESH:C472645), doxorubicin (MESH:D004317), phosphatidic acid (MESH:D010712), etoposide (MESH:D005047), polyacrylamide (MESH:C016679), polydimethylsiloxane (MESH:C013830), glycogen (MESH:D006003), bleomycin (MESH:D001761), glucose (MESH:D005947), docetaxel (MESH:D000077143), HA (MESH:D006820)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** MDA-MB-231 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0062), MCF10A — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0598), U87 MG — Homo sapiens (Human), Glioblastoma, Cancer cell line (CVCL_0022), PC-9 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_B260), Hepa1-6 — Mus musculus (Mouse), Hepatocellular carcinoma of the mouse, Cancer cell line (CVCL_0327), HFL1 — Homo sapiens (Human), Finite cell line (CVCL_0298), PLEC — Homo sapiens (Human), Osteosarcoma, Cancer cell line (CVCL_A4GM), A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), Cal27 — Homo sapiens (Human), Tongue adenosquamous carcinoma, Cancer cell line (CVCL_1107), HO8910 — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_6868), U251 — Homo sapiens (Human), Astrocytoma, Cancer cell line (CVCL_0021), KATO III — Homo sapiens (Human), Down syndrome, Cancer cell line (CVCL_0371), MHCC97H — Homo sapiens (Human), Adult hepatocellular carcinoma, Cancer cell line (CVCL_4972), HT29 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0320), Hep3B — Homo sapiens (Human), Childhood hepatocellular carcinoma, Cancer cell line (CVCL_0326), A2780 — Homo sapiens (Human), Ovarian endometrioid adenocarcinoma, Cancer cell line (CVCL_0134), SK-OV-3 — Homo sapiens (Human), Ovarian serous cystadenocarcinoma, Cancer cell line (CVCL_0532)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12943065/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12943065/full.md

## References

100 references — full list in the complete paper: https://tomesphere.com/paper/PMC12943065/full.md

---
Source: https://tomesphere.com/paper/PMC12943065